Lymphoma Specialized Program of Research Excellence (SPORE)

描述（由申请方提供）：尽管淋巴恶性肿瘤有进展，但大多数仍无法治愈，并导致患者死亡。该爱荷华州/梅奥诊所淋巴瘤孢子（UI/MC孢子）的大学是一个非常成功的转化研究计划，利用的霍尔顿综合癌症中心在爱荷华州和马约诊所综合癌症中心-两个NCI指定的综合癌症中心的转化淋巴瘤计划的综合优势。在上一个供资期间，UI/MC的工作效率很高。科学成就包括探索一种新的治疗剂，免疫刺激性CpG ODN，作为一种潜在的治疗B细胞恶性肿瘤的潜力，新的成像方法的发展，可能会影响我们对淋巴瘤生物学的理解，并调查生物标志物，可能有显着的影响淋巴瘤的管理转化研究。作为UI/MC SPORE的一部分，已经启动了五项早期治疗临床试验，其中包括在爱荷华州和马约招募受试者的四项研究。自2002年启动UI/MC SPORE以来，96例受试者已入组治疗试验，17例入组新型成像试验。作为UI/MC淋巴瘤孢子分子流行病学资源的一部分，在爱荷华州和马约收集了1331名受试者的DNA和广泛的临床数据，作为鉴定有助于淋巴瘤发生和治疗反应的遗传因素的工具，该资源将越来越有价值。 此更新申请旨在加快UI/MC SPORE的进展，包括四个研究项目，四个核心资源，以及职业发展和发展研究计划。具体项目如下： 1)B细胞恶性肿瘤免疫治疗的新途径 2)淋巴瘤的信号转导抑制剂治疗 3)APRIL和BLyS在B细胞NHL中的生物学和流行病学研究 4)B细胞非霍奇金淋巴瘤肿瘤微环境中的调节性T细胞核心资源包括管理、生物统计学和生物信息学、生物标本和支持临床试验和UI/MC SPORE的分子流行病学资源的临床研究。 UI/MC SPORE内的所有单位都致力于利用这两个机构的资源，加快将发现转化为新的更好的方法来预防和治疗淋巴瘤。

DESCRIPTION (provided by applicant): Despite progress in lymphoid malignancies, most are still incurable and lead to the death of the patient. The University of Iowa/Mayo Clinic Lymphoma SPORE (UI/MC SPORE) is a highly successful translational research program that takes advantage of the combined strengths of the translational lymphoma programs of the Holden Comprehensive Cancer Center at the University of Iowa and the Mayo Clinic Comprehensive Cancer Center - two NCI-designated comprehensive cancer centers. During the prior funding period, the UI/MC has been highly productive. Scientific accomplishments include translational studies exploring the potential of a novel therapeutic agent, immunostimulatory CpG ODN, as a potential treatment for B cell malignancies, development of novel approaches to imaging that could impact on our understanding of lymphoma biology, and investigation into biomarkers that could have a significant impact on management of lymphoma. Five early phase therapeutic clinical trials have been opened as part of the UI/MC SPORE, including four studies that have accrued subjects at both Iowa and Mayo. Since initiation of the UI/MC SPORE in 2002, 96 subjects have been enrolled on therapeutic trials and 17 on novel imaging trials. DNA and extensive clinical data have been collected on 1331 subjects at Iowa and Mayo as part of the UI/MC Lymphoma SPORE Molecular Epidemiologic Resource which will be increasingly valuable as a tool for identifying genetic factors that contribute to lymphomagenesis and response to therapy. This renewal application is designed to accelerate the progress of the UI/MC SPORE and consists of four research projects, four core resources, and the Career Development and Developmental Research Programs. Specific projects are as follows: 1) A novel approach to the immunotherapy of B cell malignancies 2) Signal transduction inhibitor therapy for lymphoma 3) Biology and Epidemiology of APRIL and BLyS in B-cell NHL 4) Regulatory T-cells in the tumor microenvironment of B-cell non-Hodgkin lymphoma Core resources include Administration, Biostatistics and Bioinformatics, Biospecimens, and Clinical Research that supports both clinical trials and the Molecular Epidemiology Resource of the UI/MC SPORE. All units within the UI/MC SPORE work to draw on the resources of both institutions to expedite the translation of discoveries into new and better approaches to the prevention and treatment of lymphoma.